'Biosimilar' drugs poised to penetrate market.
Heidi
H
Ledford
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000096:biosynthesis / Q000627:therapeutic use; D001688:Biological Products / Q000191:economics* / Q000592:standards / Q000600:supply & distribution* / Q000627:therapeutic use; D001709:Biotechnology / Q000191:economics / Q000331:legislation & jurisprudence; D002986:Clinical Trials as Topic / Q000639:trends; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D016568:Drugs, Generic / Q000009:adverse effects / Q000191:economics* / Q000592:standards / Q000600:supply & distribution*; D005060:Europe; D006801:Humans; D040541:Marketing / Q000639:trends*; D000069283:Rituximab; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001688:Biological Products; D016568:Drugs, Generic; D000069283:Rituximab